It’s been a mere five years since Johnson & Johnson launched their blockbuster diabetes drug Invokana. In that time, it has climbed into the top-ten most prescribed medications for diabetes, with billions of dollars in sales.
It was 2013, and the launch of Johnson & Johnson’s drug Invokana ushered in a new class of type 2 diabetes medications...
While type 2 diabetes drugs are among the fastest-growing segment on the market, they’re not without risk of serious side effects. In just the past 5 years, studies have linked them to kidney disease, bladder cancer, pancreatitis and ketoacidosis.
Last week, it emerged Johnson & Johnson’s Janssen unit has asked the FDA to approve expanded uses of its diabetes drug Invokana (canagliflozin), to include reducing the risk of major cardiovascular injuries and death in those with diabetes.
The FDA added yet another warning to the popular diabetes drug Invokana last week, mixing up an already crowded market for SGLT-2 inhibitors and raising concerns for millions of patients that rely on the medication.
